Mylan NV fell as much as 6 percent after Wells Fargo analyst David Maris said the generic drugmaker could be the next target of public criticism on drug price increases.
In a report titled “Is Mylan Next in Line for Pricing Scrutiny?,” Maris said the generic drugmaker could follow companies like Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG, which faced intense criticism and have had to appear before Congress to defend their drug-pricing tactics.
